Tempus AI announces expansion of Tempus One
Tempus AI (TEM) announced the expansion of Tempus One-its generative AI clinical assistant-with direct integration into electronic health record, EHR, systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
PAVmed Subsidiary, Veris Health, Enters into Strategic Partnership Agreement with The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Long-term strategic partnership and commercial transition follow successful completion of pilot program of Veris Cancer Care Platform™ at OSUCCC – James NEW YORK, June 3, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris has entered into a strategic partnership agreement with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center. This agreement follows the successful completion of a pilot program which enrolled patients across several OSUCCC – James cancer care service lines on the Veris Cancer Care Platform™. Pursuant to the agreement Veris and OSUCCC – James entered into a long-term, multi-project strategic partnership to utilize, and further the development and commercialization of the Veris Cancer Care Platform and its implantable physiologic monitor. The agreement includes expansion of commercial utilization of the platform across cancer care service lines; full electronic health record (EHR) integration; initiation of a large clinical registry of patients enrolled on the platform to be launched in the coming weeks; and launch of a large clinical trial of patients receiving the implantable physiologic monitor, to be launched upon FDA clearance, expected next year. It also calls for close collaboration on the development of clinical cancer care pathways, platform software enhancements, and best practices for clinical use of the implantable physiological monitor. "We are thrilled to advance our strategic partnership with OSUCCC – James, one of the largest and most prestigious academic cancer centers in the nation, following the successful completion of a pilot program demonstrating the strong clinical utility of our platform," said Brian deGuzman, M.D., Chief Operating Officer of Veris Health. "This commercial transition represents a major milestone for Veris. We look forward to working closely with the OSUCCC – James team to enhance the care of thousands of cancer patients there every year." "At the OSUCCC – James, delivering personalized, world-class cancer care remains our top priority," said David Cohn, M.D., M.B.A., Chief Operating Officer and Chair of Gynecologic Oncology at The James Cancer Hospital and Solove Research Institute. "After a successful pilot program, we are excited to be entering into a long-term strategic partnership with Veris Health to expand access to the Veris Cancer Care Platform and enhance the care of our patients." The Veris Cancer Care Platform is a comprehensive digital cancer care platform with remote physiological data collection, symptom reporting, telehealth capability, and electronic health record integration. The platform seeks to offer enhanced personalized cancer care through the early detection of complications, reduced unplanned hospitalizations, the provision of longitudinal trends of physiological and clinical data, data-driven risk management tools, and increased patient and provider satisfaction. Cancer patients enrolled on the platform receive a VerisBox™ of Veris-branded connected health care devices which transmit physiologic data to the cloud-based clinician portal via embedded cellular connections. A complementary patient portal enables patients to report symptoms, as well as general health and quality of life parameters, to their cancer care team through the Veris patient smartphone app. The app also allows patients to invite caretakers and family members to follow along on their cancer care journey. Veris is also developing an implantable physiological monitor, designed to be implanted alongside a vascular access port, which will interface with the Veris Cancer Care Platform. The implantable monitor will further enhance the clinical and commercial value of the platform by providing remote physiologic data independent of patient compliance. Cancer centers and oncology practices interested in learning more about Veris and the Veris Platform, please visit to contact a company representative. About PAVmed and Veris PAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its majority-owned subsidiary, Veris Health Inc., is a digital health company whose lead product is a digital cancer care platform with physiologic data collection, symptom reporting and telehealth functions, designed to improve personalized cancer care through remote patient monitoring. Veris has also been developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris cancer care platform. Its other majority-owned subsidiary, Lucid Diagnostics, is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. For more and for more information about PAVmed, please visit For more information about Veris Health, please visit For more information about Lucid Diagnostics, please visit About The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (the "OSUCCC – James"), is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic health center and a freestanding cancer hospital on the campus of one of the nation's largest public universities. The OSUCCC – James has been designated as an NCI Comprehensive Cancer Center since 1976. Also, it is one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer agents provided by the NCI. As the cancer program's adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet® recognition, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors, more than 1.1 million square feet and 356 inpatient beds, The James is the third-largest cancer hospital in the nation. The OSUCCC – James is a global leader in such emerging disciplines as cellular therapy and immuno-oncology. In 2017, the OSUCCC – James was among the first hospitals in the United States to offer the first cellular therapy for blood cancers, known as CAR T-cell therapy, and is playing a major role in the continuing development of this and other cellular therapies. To learn more about cancer treatment and clinical trials at the OSUCCC – James, visit Forward-Looking Statements This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's clinical and preclinical studies; whether and when PAVmed's products are cleared by regulatory authorities; market acceptance of PAVmed's products once cleared and commercialized; PAVmed's ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond PAVmed's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's future operations, see Part I, Item 1A, "Risk Factors," in PAVmed's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. View original content to download multimedia: SOURCE PAVmed Inc. Sign in to access your portfolio
Yahoo
13 hours ago
- Yahoo
Sage Growth Partners Announces New Marketing and Communications Partnership with Valer
Partnership to provide demand generation, thought leadership, and media services BALTIMORE, June 3, 2025 /PRNewswire/ -- Sage Growth Partners (SGP), a healthcare growth strategy and marketing firm, has announced its selection as the communications and marketing agency partner for Valer. Valer's technology simplifies and speeds prior authorization by automating submissions, status checking, verification, reporting and EHR synchronization across all mid-to-large sized healthcare settings, specialties and payers. Valer also gives providers insight into payer ruling patterns and patient access team productivity metrics—data that isn't currently available anywhere else. "Valer helps to ensure visibility across the entire prior authorization workflow," said Steve Kim, MD, co-founder and CEO. "We eliminate the burdens of manual processes that currently inundate our healthcare system and enable organizations to simplify and speed prior authorization. It was important for us to choose a marketing agency partner that has a deep understanding of our technology and data and is able to quickly generate measureable results for us. Sage perfectly meets that criteria." The partnership between the companies will primarily focus on elevating Valer's brand awareness in the market, by accelerating deal cycles, nurturing client prospects and creating insightful thought leadership and media materials. "Sage is widely-recognized for helping healthcare organizations solve complex problems, create value and drive growth in competitive markets," said Boh Hatter, Sage Growth Partners' Chief Marketing Officer and one of the firm's managing partners. "Our deep market experience allows us to quickly deliver results for our clients and we are grateful for the opportunity to help Valer further achieve their mission of helping patients receive the care they need and deserve." For more information on Sage Growth Partners and the firm's extensive healthcare capabilities, visit About Sage Growth PartnersSage Growth Partners is a healthcare growth strategy and marketing firm with deep expertise in market research, go-to market strategy, and marketing communications. Founded in 2005, the company's extensive domain experience ensures that healthcare organizations thrive amid the complexities of a rapidly changing marketplace. Sage Growth Partners serves clients across the full healthcare spectrum, including Press Ganey, GE Healthcare, Medecision, ProgenyHealth, Kyruus Health; Best Buy Health, New Jersey Brain and Spine, the National Minority Health Association, and Philips Healthcare. For more information, visit About ValerFounded in 2012, Valer® provides a premium solution for simplifying and speeding prior authorization management for hospitals, health systems, physician practices, and other healthcare settings. With software customized for each client's workflow and EHR, Valer enables users to automatically submit, verify, and manage prior authorizations for all payer plans from a single platform. Recognized as a 2024 AVIA Marketplace Top Prior Authorization Company, Valer improves staff productivity, financial performance, and patient satisfaction. Valer is Built Around You. For more information, visit For More InformationJohn Gonda616-309-4888jgonda@ View original content to download multimedia: SOURCE Sage Growth Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 hours ago
- Yahoo
Tebra Launches AI Note Assist, Reducing Clinical Documentation Time by 50% for Independent Practices
New HIPAA-compliant AI technology integrated into Tebra's EHR platform reduces documentation time by up to 50%, helping providers focus more on patient care NEWPORT BEACH, Calif., June 03, 2025--(BUSINESS WIRE)--Tebra, the all-in-one platform for independent healthcare providers, today announced the launch of AI Note Assist, a HIPAA-compliant ambient documentation solution that reduces note-taking time by up to 50%, while seamlessly integrating into existing clinical workflows. This launch addresses a critical challenge: Physicians spend an average of 15.5 hours per week on paperwork and administrative tasks, contributing to widespread burnout that affects nearly 50% of practicing doctors. AI Note Assist offers independent practices an immediate solution to reclaim valuable time for patient care. Seamlessly embedded into Tebra's EHR, AI Note Assist listens during patient visits and automatically generates structured, editable clinical notes. Built with enterprise-grade security and clinically tested for accuracy, this underwent extensive validation with practicing providers to ensure reliability in real-world settings. This tool empowers providers to complete documentation twice as fast, with early adopters reporting a 50% reduction in note-taking time. "My notes used to take 30 to 60 minutes because they would be so detailed. With the Tebra AI Note Assist, each of my notes today took not even five minutes," said Angela Davis-Taylor, FNP-C, INHC, of Daisy Family Health Care. "What I like about the AI Note Assist is I can do small talk with my patient, and the AI can pick up the parts of the conversation that matter the most, and filter out what's irrelevant. So I feel like I can be myself in the room, which is comforting," added Erica Cheshire, ANP-BC, of Beaumont WELLness for Women. AI Note Assist supports multiple clinical documentation formats — including SOAP, Therapy Initial and Progress, and Psychiatric notes — and intelligently suggests ICD-10 codes based on conversation details. Providers maintain full control with the ability to review, edit, and approve notes before finalizing, ensuring clinical accuracy and completeness. "The launch of AI Note Assist is a significant milestone in our mission to empower independent practices," said Kyle Ryan, Chief Product and Technology Officer at Tebra. "Our own research shows that 82% of independent providers believe more patient time is their key competitive advantage over large healthcare networks. We're delivering powerful, affordable AI tools that help providers reclaim that advantage by working efficiently, reducing burnout, and focusing on what matters most — delivering exceptional patient care. We expect AI Note Assist to save our customers thousands of administrative hours while significantly improving provider satisfaction." The solution is available to Tebra customers immediately through their existing platform, requiring no additional hardware or software installations. This addresses a critical need, as Tebra research shows 80% of providers experiencing decreased job satisfaction directly link it to insufficient patient interaction time. Independent practices can begin reducing documentation time today while maintaining clinical quality and compliance requirements they require. For more information or to schedule a demonstration, visit About Tebra Tebra is the only all-in-one EHR+ platform built exclusively for independent healthcare practices. Designed to replace the clunky, fragmented tools built for corporate systems, Tebra connects EHR, billing, automation, telehealth, and marketing — so providers can spend less time on admin and more time with patients. More than 42,000 private practices trust Tebra to streamline operations, increase revenue, and reduce burnout — helping clinicians leave work on time and rediscover their purpose. Learn more at View source version on Contacts pr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
